CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S129-S130
DOI: 10.1055/s-0041-1727984
Abstracts
Head-Neck-Oncology: Medical Tumor Therapy

Kinase activity profiles as prognostic marker for immunotherapy in head and neck squamous cell carcinoma (HNSCC)

L Bußmann
1   Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Hals-, Nasen-, und Ohrenheilkunde, Hamburg
,
K Hoffer
3   Universitätsklinikum Hamburg-Eppendorf, UCCH Kinomics Core Facility, Hubertus Wald Tumorzentrum, Hamburg
,
C Betz
1   Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Hals-, Nasen-, und Ohrenheilkunde, Hamburg
,
C-J Busch
1   Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Hals-, Nasen-, und Ohrenheilkunde, Hamburg
,
A Münscher
5   Marienkrankenhaus Hamburg, Klinik für HNO-Heilkunde, Kopf-, Hals- und Plastische Gesichtschirurgie, Hamburg
,
G Hapke
6   Marienkrankenhaus Hamburg, Klinik für Hämatologie und Onkologie, Hamburg
,
M Kriegs
3   Universitätsklinikum Hamburg-Eppendorf, UCCH Kinomics Core Facility, Hubertus Wald Tumorzentrum, Hamburg
› Author Affiliations
› Further Information
Also available at
 

Background In the relapsed or distant metastatic situation of HNSCC, the EXTREME protocol (combination therapy with cisplatin, 5-FU and cetuximab) has been the therapy standard, so far. Recent study results led to a paradigm shift and the establishment of immune checkpoint inhibitors such as anti-PD-1-antibodies in this situation. In addition, immune check point inhibitors can also be used in platinum refractory / resistant tumors as 1st line therapy. However, as only 13-18 %  respond to therapy (overall response rate) and prognostic markers are needed to identify responders and non-responders, i) to guide non-responders to a more appropriate therapy, ii) to save them from serious side effects and iii) to enable an economical use of these expensive therapeutics. Based on the work from colleagues from the Netherlands (Hurkmans et al., ASCO 2018), we will investigate if the kinase activity in peripheral blood cells (PBMC) predicts the respond towards the treatment with PD-L1 antibodies.

Methods Blood samples from patients before and during treatment with a anti-PD-1-antibody (nivolumab or pembrolizumab) are prospectively collected and the tyrosine kinase activity profile is determined using a PamStation®12 and corresponding PamChips. Based on the patients' survival and response data, a binary clustering of patients in responders and non-responders can be performed and will be correlated with the corresponding data from the kinome analyzes.

Poster-PDF A-1301.pdf

Mildred Scheel Nachwuchszentrum HaTriCS4, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland; Brigitte und Dr. Konstanze Wegener-Stiftung



Publication History

Article published online:
13 May 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany